Phase 2 N=179 Topical Rapamycin to Erase Angiofibromas in TSC
Angiofibromas · Tuberous Sclerosis
Primary: Change From Baseline in the Facial Angiofibroma Grading Scale (AGS) Score — -13.89; -12.71; -1.39 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
X-linked Hypophosphatemia
Primary: Safety and Efficacy of Repeated SC Injections of KRN23 — 24; 1; 1; 0 Participants
Phase 2 N=1 Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome
Antiphospholipid Antibody Syndrome · End Stage Renal Disease
Primary: Number of Patients With Prevention of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) After Kidney Transplant — 1 Participants
Phase 2 N=225 A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
Advanced Non-small Cell Lung Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) (Phase I Part) — 0; 0; 2; 0 Participants
Phase 2 N=45 MK-3475 as Maintenance Therapy in Extensive Stage SCLC
Extensive Stage Small Cell Lung Carcinoma
Primary: PFS Using RECIST 1.1 — 1.4 months
Phase 2 N=10 A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
Teratoma
Primary: Progression Free Survival (PFS) — 71.4; 0.0 Days
Phase 2 N=241 A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
Open-angle Glaucoma, Ocular Hypertension
Primary: Intraocular Pressure in the Study Eye at Month 3 — 18.8; 18.1; 19.7; 19.2 mmHg
Phase 2 N=80 Metformin in Amnestic Mild Cognitive Impairment
Mild Cognitive Impairment
Primary: Change in Total Recall Score in the Selective Reminding Test — 5.7; 9.4 score on a scale — p=0.05
Phase 2 N=45 Study to Treat Major Depressive Disorder With a New Medication
Depressive Disorder · Anhedonia
Primary: Change in Ventral Striatum (VS) Activation — -0.26; 0.95; 0.176; 0.015 Bold Oxygen-level Dependent (BOLD) Signa
Phase 2 N=345 Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Hematologic Neoplasms
Primary: Phase 1 Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 Participants
Phase 2 N=23 The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity
Obesity · Sarcopenic Obesity · Sarcopenia
Primary: Change in Body Weight — 0.54; 0.04 Kilograms
Phase 2 N=38 Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan
Chronic Hepatitis C
Primary: Percentage of Subjects With Sustained Virologic Response (SVR12) 12 Weeks Post-treatment — 38 Participants
Phase 2 N=50 Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
Head and Neck Squamous Cell Carcinoma · Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma · Recurrent Nasopharynx Carcinoma
Primary: Incidence of Toxicity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 1; 1; 0; 1 Participants
Phase 2 N=60 Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction
Meibomian Gland Dysfunction
Primary: Meibomian Gland Secretion Appearance at Visit 4 (Day 168) — 0.80; 0.96 units on a scale
Phase 2 N=59 A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)
Refractory Chronic Cough
Primary: Change in Awake Objective Cough Frequency on Log-transformed Scale - Cohort 1 — 0.56; 0.95; 0.46; 0.95 Log coughs/hour — p=0.0055